1. Characteristics of included studies
João Costa, et al. BMJ; 2006;332:

2. Event rate for major coronary events in primary prevention trials (mean weighted follow-up 4.5 years)
João Costa, et al. BMJ; 2006;332:

3. Event rate for major coronary events in secondary prevention trials (mean weighted follow-up 5.1 years)
João Costa, et al. BMJ; 2006;332:

4. Primary prevention of major coronary events
João Costa, et al. BMJ; 2006;332:

5. Secondary prevention of major coronary events
João Costa, et al. BMJ; 2006;332:

6. Secondary prevention of coronary heart disease death
João Costa, et al. BMJ; 2006;332:

7. Secondary prevention of non-fatal myocardial infarction
João Costa, et al. BMJ; 2006;332:

8. Secondary prevention of myocardial revascularisation procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty)
João Costa, et al. BMJ; 2006;332:

9. Primary prevention of major coronary events
João Costa, et al. BMJ; 2006;332:

10. Number needed to treat and benefit for 1000 patients
João Costa, et al. BMJ; 2006;332:

11. Secondary prevention of stroke
João Costa, et al. BMJ; 2006;332:

12. Change in blood lipid concentrations
HDL-C=high density lipoprotein cholesterol;
LDL-C=low density lipoprotein cholesterol
(no data for total cholesterol were available in VA-HIT)
João Costa, et al. BMJ; 2006;332: